Cardio Diagnostics (CDIO) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Trinity Biotech is the larger company by market cap ($5.1 million vs $4.7 million), about 1.1 times the size. Trinity Biotech converts more of its revenue into profit, with a net margin of -51.6% versus -43832.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDIO | TRIB |
|---|---|---|
| Share price | $1.60 | $6.24 |
| Market cap | $4.74M | $5.07M |
| 1-day change | -3.03% | +13.76% |
| EPS (TTM) | $-2.52 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.82K | $61.55M |
| Revenue growth (YoY) | -57.51% | +8.31% |
| Net income (latest FY) | $-6.50M | $-31.79M |
| Gross margin | — | 34.83% |
| Operating margin | -43737.46% | -34.38% |
| Net margin | -43832.49% | -51.64% |
| 52-week high | $7.91 | $52.50 |
| 52-week low | $0.97 | $4.54 |
| Distance from 52-week high | -79.77% | -88.11% |
| Average volume | 26.91K | 13.54K |
| Shares outstanding | 2.96M | 813.13K |
| Employees | 15 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Trinity Biotech is more profitable, keeping -51.6 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
- Trinity Biotech grew revenue faster in its latest fiscal year (+8.31% vs -57.51%).
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
CDIO vs TRIB FAQ
Which is bigger, Cardio Diagnostics or Trinity Biotech?
Trinity Biotech (TRIB) is larger, with a market capitalization of $5.07M compared with $4.74M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.